Immunic Inc. (IMUX) PT Raised to $61 at BMO Capital, Following Drug Trial Results
Tweet
Share
E-mailGet Alerts IMUX Hot Sheet
Price: $12.90 +1.26%
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 60
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 60
Join SI Premium – FREE
BMO Capital analyst George Farmer raised the price target on Immunic Inc. (NASDAQ: IMUX) to $61.00 (from $40.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Macquarie Downgrades Mercari, Inc (4385:JP) (MRCIF) to Neutral
- TS Tech Co Ltd (7313:JP) PT Raised to JPY1,600 at JPMorgan
- JPMorgan Upgrades Nippon Chemi-Con (6997:JP) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
